Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Crystal Gateway Marriott

23 sep 2026 8:15 a.m. - 25 sep 2026 12:45 p.m.

1700 Richmond Highway, Arlington, VA 22202, USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Session 11: Grand Q&A Panel

Session Chair(s)

René  Thürmer

René Thürmer

Deputy Head of the Unit Pharmaceutical Biotechnology BfArM, Federal Institute for Drugs and Medical Devices, Germany

This session will allow open discussion between the audience and an esteemed panel of experts to ask any remaining questions. Please note: due to the high volume of questions, not all will be answered live at the conference

Speaker(s)

Hobart  Rogers, PharmD, PhD

Speaker

Hobart Rogers, PharmD, PhD

Pharmacologist, CDER, FDA, United States

Andrew  Slugg, MBA, MS

Speaker

Andrew Slugg, MBA, MS

Senior Vice President, Global Head of Regulatory Sciences, Alnylam Pharmaceuticals, United States

Jennifer  Sisler, PhD

Speaker

Jennifer Sisler, PhD

Director, Eli Lilly and Company, United States

Xuan  Chi, DRSc, MD

Speaker

Xuan Chi, DRSc, MD

Supervisory Pharmacologist, CDER, FDA, United States

Lubomir  Nechev, PhD

Speaker

Lubomir Nechev, PhD

Chief CMC Officer, Alnylam Pharmaceuticals, United States

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.